Gestisci la mia rete▼ Modifica aspetto

Cerca S.H.R.O. Salute Italia

- <u>SHRO Media Press</u>
- <u>Esci</u>



Professional social network di Antonio Giordano

- <u>Home</u>
- <u>Area Forum</u>
- <u>Blog</u>
- Foto
- <u>Membri</u>
- <u>Video</u>
- <u>Eventi</u>
- <u>Rassegna Stampa</u>
- <u>Mission SHRO</u>
- <u>Biografia prof.Giordano</u>
- <u>YouTube</u>
- <u>Invita</u>
- La mia rete
- Tutte le discussioni
- Le mie discussioni
- Impostazioni
- <u>Aggiungi</u>
- <u>Opzioni</u>▼



Plea for a Correct Use of Stem Cells in Therapy

- Post aggiunto da SHRO Media Press il 26 Maggio 2013 alle 11:40 in Titolo di esempio (Modifica)
- Visualizza discussioni

The "Stem Cell Research Italy" Association (<u>www.stemcellitaly.org</u>) and the "Sbarro Health Research Organization" (<u>www.shro.org</u>) make a public plea for a correct use of stem cell therapy in Italy and Europe.

Stem Cell Research Italy (SCR Italy) strongly endorses the point of view of eminent scientists who published a commentary on the regulation of stem cell therapy in Europe (Bianco et al "Regulation of stem cell therapies under attack in Europe: for whom the bell tolls" *EMBO J.* 2013 May 3. doi: 10.1038/emboj.2013.114).

In the present plea SCR quotes the hot topic issues that were addressed in the commentary.

The Italian Parliament is debating a new law that would make it legal to practice an unproven stem cell treatment in public hospitals. The treatment, offered by a private non-medical organization, may not be safe, lacks a rationale, and violates current national laws and European regulations. This case raises multiple concerns, most prominently the urgent need to protect patients who are severely ill, exposed to significant risks, and vulnerable to exploitation.

It must be underlined that stem cells are not a homogeneous class of cells; 'stem cells' are not one-size-fits-all cures. There are different kinds of stem cells in different tissues, and even when the appropriate stem cell is selected for an indication it takes years of research to learn how to administer the stem cell safely and effectively.

Empiricism as a productive approach in medicine is often invoked as a reason to conduct trials with stem cells, blind of any putative mechanism of action.

Conducting formal, regulated, transparent clinical trials using stem cells can be legitimate, even if based on a partial or weak rationale. It is also, however, expensive and highly likely to be uninformative. Scientific approach must be robust before one embarks on a clinical trial. Mechanistic insight is not a dispensable intellectual luxury. It is specifically required to develop effective therapies. It is to this end that we need mechanisms and rationale.

A model of 'translational medicine' has been subliminally accepted by many scientists. The scheme is driven by the pressure to effect the rapid translation of data from the bench. Premature translation of provisional data and concepts in the stem cell field, in conjunction with loosened regulation, can perhaps bring to the market products, but cannot provide solutions for diseases.

On this premise, scientists must clearly inform public opinion and authorities on the potential risks of stem cell therapy to avoid media campaign

vowing the right of sick people to have access stem cell therapy for "compassionate use". It has to be firmly rejected the argument offered by media and public opinion of a compassionate use of stem cells: there is no compassion without safety and efficacy. Exposing the weakest people to unknown risks is ethically unacceptable. Recourse to unproven and unsafe therapy is said to be 'compassion', or to fall into an arbitrary category of 'compassionate treatment'. This is not the case at all. Compassion only applies when one offers a safe and potentially effective remedy. That a remedy is effective must be supported by published clinical data. If such data are not available, there is no legitimate assumption of effectiveness in the individual patient, and therefore no 'compassion'.

In conclusion SCR Italy strongly agree with the notion that only rigorous science and rigorous regulation can ensure translation of science into effective therapies rather than into ineffective market products, and mark, at the same time, the sharp distinction between the striving for new therapies and the deceit of patients.

Signed by Board of Directors on behalf of SCR Italy

Umberto Galderisi Assunta Pandolfi Marilena Cipollaro Bruno Bonetti Patrizia Dell'Era Giovanni Di Bernardo Roberta Di Pietro Roberta Piva Stefano Pluchino

This plea has been endorsed by:

IPLASS - International Placenta Stem Cell Society

John Barrett Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Helen Blau

Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cells and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA

Dominique Bonnet

Medical Oncology, St Bartholomew's Hospital and Medical School, London, UK

Marianne Bronner

Division of Biology at the California Institute of Technology, California Institute of Technology, Pasadena, CA, USA

Connie Eaves Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada

Robert G. Hawley Department of Anatomy and Regenerative Biology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Antonio Giordano Sbarro Institute For Cancer Research And Molecular Medicine, Temple University, Philadelphia, PA, USA

John Kessler Department of Neurology, Northwestern University Stem Cell Institute, Northwestern University's Feinberg School of Medicine, Chicago, IL, USA

Paul W. Kincade Immunobiology & Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Ulrich Martin Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO) at Hannover Medical School (MHH), Hannover, Germany

Eva Mezey National Institute of Health, NIDRC, CSDB, Bethesda, MD, USA

Charles E. Murry Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

Shinichi Nishikawa RIKEN Center for Developmental Biology (CDB), Laboratory for Stem Cell Biology, Kobe, Japan

Graham Parker

Wayne State University School of Medicine, Carman and Ann Adams Department of Pediatrics, Detroit, MI, USA

Darwin Prockop

Texas A&M Health Science Center, College of Medicine, Institute for Regenerative Medicine, Scott & White Hospital, Temple, TX, USA

Tom Rando

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

Brent Reynolds

Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, USA

LOOK ALSO:

http://www.repubblica.it/salute/medicina/2013/05/21/news/stamina 1 ... http://www.adnkronos.com/IGN/Daily_Life/Benessere/Staminali-appello... http://scienza.panorama.it/salute/Staminali-appello-scienziati-tute... http://www.liberoquotidiano.it/news/1246440/Staminali-appello-scien... http://www.wallstreetitalia.com/article/1572333/salute/staminali-ap... http://www.agi.it/research-e-sviluppo/notizie/201305211614-eco-rt10... http://www.padovanews.it/speciali/salute/209244-staminali-appello-s...

Condividi Twitter Facebook

Visualizzazioni: 2

▼ Rispondi

Carica file

Non seguire più – Non inviarmi un'email quando qualcuno risponde

Aggiungi risposta

SHRO Media Press

<u>Esci</u>

- Posta in arrivo
- <u>Amici</u> <u>Invita</u>
- Impostazioni

In attesa di approvazione

- <u>1 Discussion Topic</u>
- <u>1 Nuovo membro</u>

Rubrica Giordano su Doctor Mag





Picasa BLOG foto nuovi laboratori SHRO

10 27 2009 Sbarro Dedication Antonio Giordano, AWH, Sam Smith, Mario Civera



10 27 2009 Sbarro Dedication Antonio Giordano, AWH, Sam Smith, Mario Civera

• <u>Altro...</u>

CAMPANIA SU WEB



CAMPANIA SU WEB

© 2013 Creato da SHRO Media Press. Tecnologia NING | GLAM SOCIAL

Badge | Guida | Termini del servizio